As expected, NF-κB pathway was activated along with an increased expression of CCL5 after the administration of tucidinostat treatment in CT26 cancer cell lines, and this upregulation of CCL5 expression was abrogated upon pharmacological NF-κB inhibition using BAY11-7082 (Fig. 2d, e). Here, CCL5 is linked to cancer.